Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Given Consensus Rating of “Reduce” by Brokerages

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) has earned an average recommendation of “Reduce” from the eleven brokerages that are presently covering the stock, MarketBeat.com reports. Five research analysts have rated the stock with a sell rating and six have assigned a hold rating to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $23.5667.

FMS has been the subject of a number of recent analyst reports. Sanford C. Bernstein upped their price objective on Fresenius Medical Care AG & Co. KGaA from $25.50 to $25.80 and gave the company a “market perform” rating in a research note on Thursday, August 6th. Wall Street Zen downgraded shares of Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “hold” rating in a report on Saturday, May 9th. Citigroup restated a “neutral” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Friday, July 17th. Zacks Research upgraded shares of Fresenius Medical Care AG & Co. KGaA from a “strong sell” rating to a “hold” rating in a report on Monday, July 6th. Finally, BNP Paribas Exane lowered shares of Fresenius Medical Care AG & Co. KGaA from a “neutral” rating to an “underperform” rating and set a $19.90 price objective on the stock. in a research report on Tuesday, July 28th.

Institutional Investors Weigh In On Fresenius Medical Care AG & Co. KGaA

A number of hedge funds have recently modified their holdings of the stock. Morgan Stanley grew its holdings in Fresenius Medical Care AG & Co. KGaA by 47.2% during the fourth quarter. Morgan Stanley now owns 2,939,839 shares of the company’s stock valued at $70,027,000 after purchasing an additional 942,497 shares during the period. Pzena Investment Management LLC raised its stake in shares of Fresenius Medical Care AG & Co. KGaA by 2.0% in the first quarter. Pzena Investment Management LLC now owns 15,052,822 shares of the company’s stock valued at $339,592,000 after buying an additional 299,986 shares during the period. Bank of America Corp DE raised its stake in shares of Fresenius Medical Care AG & Co. KGaA by 279.7% in the second quarter. Bank of America Corp DE now owns 337,316 shares of the company’s stock valued at $9,637,000 after buying an additional 248,477 shares during the period. ABC Arbitrage SA lifted its position in shares of Fresenius Medical Care AG & Co. KGaA by 1,136.0% during the 4th quarter. ABC Arbitrage SA now owns 249,800 shares of the company’s stock valued at $5,950,000 after buying an additional 229,589 shares during the last quarter. Finally, Integral Health Asset Management LLC grew its stake in shares of Fresenius Medical Care AG & Co. KGaA by 44.4% during the 4th quarter. Integral Health Asset Management LLC now owns 650,000 shares of the company’s stock worth $15,483,000 after acquiring an additional 200,000 shares during the period. Institutional investors own 8.37% of the company’s stock.

Fresenius Medical Care AG & Co. KGaA Price Performance

Shares of NYSE FMS opened at $23.07 on Monday. Fresenius Medical Care AG & Co. KGaA has a twelve month low of $20.02 and a twelve month high of $27.64. The stock’s 50 day moving average price is $23.94 and its 200-day moving average price is $23.12. The company has a market capitalization of $12.39 billion, a PE ratio of 11.95, a PEG ratio of 4.29 and a beta of 0.77. The company has a quick ratio of 0.75, a current ratio of 1.07 and a debt-to-equity ratio of 0.43.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last issued its quarterly earnings results on Monday, August 3rd. The company reported $0.66 EPS for the quarter, beating analysts’ consensus estimates of $0.62 by $0.04. The company had revenue of $5.55 billion during the quarter, compared to the consensus estimate of $5.48 billion. Fresenius Medical Care AG & Co. KGaA had a return on equity of 9.28% and a net margin of 4.83%. On average, equities analysts anticipate that Fresenius Medical Care AG & Co. KGaA will post 2.25 EPS for the current year.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.